Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 3Lymphoid 2Other hematologic neoplasm 1Myeloid 1CNS 1

Conditions

Myelodysplastic Syndromes 360Leukemia, Myeloid, Acute 301Myeloproliferative Disorders 155Leukemia, Myelogenous, Chronic, BCR-ABL Positive 141Precursor Cell Lymphoblastic Leukemia-Lymphoma 115Primary Myelofibrosis 103Leukemia, Myelomonocytic, Chronic 89Lymphoma, Non-Hodgkin 76Leukemia 71Polycythemia Vera 64Multiple Myeloma 55Hodgkin Disease 50Hematologic Neoplasms 49Leukemia, Lymphocytic, Chronic, B-Cell 44Leukemia, Biphenotypic, Acute 41Thrombocythemia, Essential 40Lymphoma 40Myelodysplastic-Myeloproliferative Diseases 32Neoplasms 29Leukemia, Myeloid, Chronic-Phase 28Anemia, Refractory, with Excess of Blasts 24Recurrence 23Anemia, Aplastic 21Lymphoma, Mantle-Cell 20Lymphoma, Follicular 20Hematologic Diseases 20Burkitt Lymphoma 20Blastic Plasmacytoid Dendritic Cell Neoplasm 20Blast Crisis 20Histiocytosis, Langerhans-Cell 19

Interventions

luspatercept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
beta-Thalassemia × Myeloid × 1 year × Clear all
NCT04064060 2026-05-28

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Celgene

Phase 3 Recruiting
665 enrolled
Myeloid

Myelodysplastic Syndromes, Myeloproliferative Disorders, beta-Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡